228 related articles for article (PubMed ID: 35020778)
21. Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.
Rockstroh A; Wolf J; Fertey J; Kalbitz S; Schroth S; Lübbert C; Ulbert S; Borte S
Emerg Microbes Infect; 2021 Dec; 10(1):774-781. PubMed ID: 33830901
[TBL] [Abstract][Full Text] [Related]
22. Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection.
Yang Y; Yang M; Peng Y; Liang Y; Wei J; Xing L; Guo L; Li X; Li J; Wang J; Li M; Xu Z; Zhang M; Wang F; Shi Y; Yuan J; Liu Y
Nat Microbiol; 2022 Mar; 7(3):423-433. PubMed ID: 35132197
[TBL] [Abstract][Full Text] [Related]
23. Long-Term Humoral Immune Response in Persons with Asymptomatic or Mild SARS-CoV-2 Infection, Vietnam.
Mai HK; Trieu NB; Long TH; Thanh HT; Luong ND; Huy LX; Nguyet LA; Man DNH; Anderson DE; Thanh TT; Chau NVV; Thwaites G; Wang LF; Van Tan L; Hung DT
Emerg Infect Dis; 2021 Feb; 27(2):663-666. PubMed ID: 33496647
[TBL] [Abstract][Full Text] [Related]
24. Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19.
Harrington WE; Trakhimets O; Andrade DV; Dambrauskas N; Raappana A; Jiang Y; Houck J; Selman W; Yang A; Vigdorovich V; Yeung W; Haglund M; Wallner J; Oldroyd A; Hardy S; Stewart SWA; Gervassi A; Van Voorhis W; Frenkel L; Sather DN
Cell Rep Med; 2021 Apr; 2(4):100253. PubMed ID: 33842901
[TBL] [Abstract][Full Text] [Related]
25. Time series analysis and mechanistic modelling of heterogeneity and sero-reversion in antibody responses to mild SARS‑CoV-2 infection.
Manisty C; Treibel TA; Jensen M; Semper A; Joy G; Gupta RK; Cutino-Moguel T; Andiapen M; Jones J; Taylor S; Otter A; Pade C; Gibbons J; Lee J; Bacon J; Thomas S; Moon C; Jones M; Williams D; Lambourne J; Fontana M; Altmann DM; Boyton R; Maini M; McKnight A; Chain B; Noursadeghi M; Moon JC
EBioMedicine; 2021 Mar; 65():103259. PubMed ID: 33662833
[TBL] [Abstract][Full Text] [Related]
26. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition.
Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G
Front Immunol; 2022; 13():830710. PubMed ID: 35173741
[TBL] [Abstract][Full Text] [Related]
27. Asymptomatic and symptomatic SARS-CoV-2 infections elicit polyfunctional antibodies.
Dufloo J; Grzelak L; Staropoli I; Madec Y; Tondeur L; Anna F; Pelleau S; Wiedemann A; Planchais C; Buchrieser J; Robinot R; Ungeheuer MN; Mouquet H; Charneau P; White M; Lévy Y; Hoen B; Fontanet A; Schwartz O; Bruel T
Cell Rep Med; 2021 May; 2(5):100275. PubMed ID: 33899033
[TBL] [Abstract][Full Text] [Related]
28. Case-Control Study of Individuals with Discrepant Nucleocapsid and Spike Protein SARS-CoV-2 IgG Results.
Wang H; Wiredja D; Yang L; Bulterys PL; Costales C; Röltgen K; Manalac J; Yee J; Zehnder J; Shi RZ; Boyd SD; Pinsky BA
Clin Chem; 2021 Jul; 67(7):977-986. PubMed ID: 33720347
[TBL] [Abstract][Full Text] [Related]
29. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
[TBL] [Abstract][Full Text] [Related]
30. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.
Solastie A; Virta C; Haveri A; Ekström N; Kantele A; Miettinen S; Lempainen J; Jalkanen P; Kakkola L; Dub T; Julkunen I; Melin M
Microbiol Spectr; 2021 Dec; 9(3):e0113121. PubMed ID: 34787485
[TBL] [Abstract][Full Text] [Related]
31. Titers of IgG and IgA against SARS-CoV-2 proteins and their association with symptoms in mild COVID-19 infection.
Abril AG; Alejandre J; Mariscal A; Alserawan L; Rabella N; Roman E; Lopez-Contreras J; Navarro F; Serrano E; Nomdedeu JM; Vidal S
Sci Rep; 2024 Jun; 14(1):12725. PubMed ID: 38830902
[TBL] [Abstract][Full Text] [Related]
32. IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases.
Tutukina M; Kaznadzey A; Kireeva M; Mazo I
Viruses; 2021 Sep; 13(10):. PubMed ID: 34696374
[TBL] [Abstract][Full Text] [Related]
33. Kinetics of Nucleocapsid, Spike and Neutralizing Antibodies, and Viral Load in Patients with Severe COVID-19 Treated with Convalescent Plasma.
Thomopoulos TP; Rosati M; Terpos E; Stellas D; Hu X; Karaliota S; Bouchla A; Katagas I; Antoniadou A; Mentis A; Papageorgiou SG; Politou M; Bear J; Donohue D; Kotanidou A; Kalomenidis I; Korompoki E; Burns R; Pagoni M; Grouzi E; Labropoulou S; Stamoulis K; Bamias A; Tsiodras S; Dimopoulos MA; Pavlakis GN; Pappa V; Felber BK
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578426
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.
Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V
J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688
[TBL] [Abstract][Full Text] [Related]
35. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.
Flehmig B; Schindler M; Ruetalo N; Businger R; Bayer M; Haage A; Kirchner T; Klingel K; Normann A; Pridzun L; Tougianidou D; Ranke MB
Viruses; 2020 Nov; 12(12):. PubMed ID: 33260809
[TBL] [Abstract][Full Text] [Related]
36. Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection.
Lapp SA; Edara VV; Lu A; Lai L; Hussaini L; Chahroudi A; Anderson LJ; Suthar MS; Anderson EJ; Rostad CA
PLoS One; 2021; 16(8):e0256482. PubMed ID: 34449792
[TBL] [Abstract][Full Text] [Related]
37. Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19.
Aguilar-Bretones M; Westerhuis BM; Raadsen MP; de Bruin E; Chandler FD; Okba NM; Haagmans BL; Langerak T; Endeman H; van den Akker JP; Gommers DA; van Gorp EC; GeurtsvanKessel CH; de Vries RD; Fouchier RA; Rockx BH; Koopmans MP; van Nierop GP
J Clin Invest; 2021 Nov; 131(21):. PubMed ID: 34499051
[TBL] [Abstract][Full Text] [Related]
38. Longitudinal clinico-serological analysis of anti-nucleocapsid and anti-receptor binding domain of spike protein antibodies against SARS-CoV-2.
Deshpande GR; Kaduskar O; Deshpande K; Bhatt V; Yadav P; Gurav Y; Potdar V; Khutwad K; Vidhate S; Salunke A; Patil C; Shingade S; Jarande K; Tilekar B; Salvi P; Patsuthe S; Dange V; Kumar S; Gurav S; Chate S; Abraham P; Sapkal G
Int J Infect Dis; 2021 Nov; 112():103-110. PubMed ID: 34543771
[TBL] [Abstract][Full Text] [Related]
39. Evolution of antibody immunity to SARS-CoV-2.
Gaebler C; Wang Z; Lorenzi JCC; Muecksch F; Finkin S; Tokuyama M; Cho A; Jankovic M; Schaefer-Babajew D; Oliveira TY; Cipolla M; Viant C; Barnes CO; Bram Y; Breton G; Hägglöf T; Mendoza P; Hurley A; Turroja M; Gordon K; Millard KG; Ramos V; Schmidt F; Weisblum Y; Jha D; Tankelevich M; Martinez-Delgado G; Yee J; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Robbiani DF; Zhao Z; Gazumyan A; Schwartz RE; Hatziioannou T; Bjorkman PJ; Mehandru S; Bieniasz PD; Caskey M; Nussenzweig MC
Nature; 2021 Mar; 591(7851):639-644. PubMed ID: 33461210
[TBL] [Abstract][Full Text] [Related]
40. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
